Search research articles
Contact Us
Filters
Showing results (1-10 of 180) with videos related to
Page
of 18
Sort By:
Blood
|
March 31, 2018
Pevonedistat, a new partner for 5-azacitidine
Amir T Fathi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2022
A New Dancing Partner for Venetoclax: Gilteritinib
Amir T Fathi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2019
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient
Amir T Fathi
The Lancet. Haematology
|
November 1, 2023
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
Amir T Fathi
Blood
|
November 23, 2013
Emergence of crenolanib for FLT3-mutant AML
Amir T Fathi
Cancer Journal (Sudbury, Mass.)
|
January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Yasmin Abaza, Amir T Fathi
Expert Review of Hematology
|
November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitor
Amir T Fathi, Mark Levis
Current Cancer Drug Targets
|
April 25, 2020
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Justin S Becker, Amir T Fathi
European Journal of Haematology
|
December 22, 2016
The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
Amir T Fathi, Yi-Bin Chen
Current Hematologic Malignancy Reports
|
March 20, 2014
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Amir T Fathi, Yi-Bin Chen
Page
of 18
Search research articles
Search
Showing results (1-10 of 180) with videos related to
Sort By:
Page
of 18
Blood
|
March 31, 2018
Pevonedistat, a new partner for 5-azacitidine
Amir T Fathi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2022
A New Dancing Partner for Venetoclax: Gilteritinib
Amir T Fathi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2019
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient
Amir T Fathi
The Lancet. Haematology
|
November 1, 2023
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
Amir T Fathi
Blood
|
November 23, 2013
Emergence of crenolanib for FLT3-mutant AML
Amir T Fathi
Cancer Journal (Sudbury, Mass.)
|
January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Yasmin Abaza, Amir T Fathi
Expert Review of Hematology
|
November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitor
Amir T Fathi, Mark Levis
Current Cancer Drug Targets
|
April 25, 2020
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Justin S Becker, Amir T Fathi
European Journal of Haematology
|
December 22, 2016
The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
Amir T Fathi, Yi-Bin Chen
Current Hematologic Malignancy Reports
|
March 20, 2014
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Amir T Fathi, Yi-Bin Chen
Page
of 18